Alkermes Plc (OQ:ALKS)

Business Focus: Biotechnology & Medical Research

Apr 24, 2024 07:00 am ET
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency in orexin levels, and the presence of cataplexy, a sudden
Apr 17, 2024 04:00 pm ET
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.
Apr 09, 2024 07:00 am ET
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia —
Apr 08, 2024 07:00 am ET
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
DUBLIN, April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients who received up to four years of treatment. LYBALVI is approved in the U.S. for the treatment of adults with schizophrenia, and for the treatme
Feb 15, 2024 06:00 am ET
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
—  Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —
Feb 08, 2024 03:00 pm ET
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results. Management will also discuss financial expectations for 2024 and provide an update on the company.
Jan 03, 2024 03:00 pm ET
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Jan 03, 2024 06:00 am ET
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment —
Dec 27, 2023 11:45 am ET
Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes
Originally published in Alkermes September 2023 Corporate Responsibility Report
Dec 20, 2023 12:15 pm ET
Corporate Governance at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility Report
Dec 18, 2023 01:45 pm ET
Alkermes' Commitment to Integrity and Compliance
NORTHAMPTON, MA / ACCESSWIRE / December 18, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility Report
Dec 14, 2023 10:45 am ET
Alkermes' Culture of Employee Engagement and Wellness
NORTHAMPTON, MA / ACCESSWIRE / December 14, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility Report
Dec 14, 2023 05:05 am ET
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
DUBLIN, Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5 million for the facility and related assets, subject to customary adjustments in accordance with the agreement. The transaction is expected to close in mid-2024, subject to certain closing conditions.
Dec 11, 2023 02:30 pm ET
Patient Advocacy and Community Engagement at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / December 11, 2023 / Alkermes
Dec 01, 2023 05:16 pm ET
Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all compa
Nov 29, 2023 03:15 pm ET
Pharmaceuticals in the Environment
NORTHAMPTON, MA / ACCESSWIRE / November 29, 2023 / Alkermes
Nov 21, 2023 03:00 pm ET
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN, Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
Nov 21, 2023 11:45 am ET
Environmental Protection & Sustainability at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Alkermes
Nov 20, 2023 01:45 pm ET
Alkermes Celebrates #Movember for Men’s Health Awareness Month
NORTHAMPTON, MA / ACCESSWIRE / November 20, 2023 / Alkermes
Nov 16, 2023 10:30 am ET
Alkermes' Waste Optimization Highlights
NORTHAMPTON, MA / ACCESSWIRE / November 16, 2023 / Alkermes
Nov 15, 2023 06:00 am ET
Alkermes Completes Separation of Oncology Business
—    Alkermes Emerges as Pure-Play, Profitable Neuroscience Company —
Nov 14, 2023 01:45 pm ET
Our Commitment to Caregivers
NORTHAMPTON, MA / ACCESSWIRE / November 14, 2023 / This month, Alkermes acknowledges the important role of family members who are caregivers for their loved ones. We applaud your selflessness, dedication and unconditional love. Your efforts inspire us to continue developing innovative medicines that have the potential to make a meaningful difference. Hear from Steve Schiavo, our Senior Vice President of Human Resources, as he reflects on how we work to support caregiving employees: https://www.alkermes.com/news-and-events/national-caregiver
Nov 13, 2023 12:45 pm ET
Product Stewardship and Environmental Impact at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / November 13, 2023 / Alkermes
Nov 10, 2023 03:00 pm ET
Caring for Caregivers: Alkermes Celebrates National Caregivers Month
NORTHAMPTON, MA / ACCESSWIRE / November 10, 2023 / Alkermes / Today and every day, we give thanks to all those providing care to loved ones. We recognize that caregiving can have an immense toll on one's overall well-being. If you or a loved one are a caregiver, it's important to know that you are not alone.
Nov 08, 2023 11:30 am ET
Environmental Health and Safety at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / November 8, 2023 / Alkermes
Nov 07, 2023 03:00 pm ET
Alkermes to Participate in the Jefferies London Healthcare Conference
DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14, 2023 at 12:00 p.m. ET (5:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Oct 31, 2023 05:08 pm ET
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
DUBLIN, Oct. 31, 2023  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was declared effective by the U.S. Securities and Exchange Commission (SEC). This Form 10 describes Alkermes' planned separation of its oncology business into Mural Oncology, which, upon completion of the separation, will be a new, independent, publicly traded company.
Oct 31, 2023 01:30 pm ET
Operating and Growing Responsibly at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Alkermes
Oct 25, 2023 07:00 am ET
Alkermes plc Reports Third Quarter 2023 Financial Results
— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year —
Oct 23, 2023 02:00 pm ET
Alkermes CEO Reflects on Living Company Purpose
NORTHAMPTON, MA / ACCESSWIRE / October 23, 2023 / Alkermes
Oct 23, 2023 08:00 am ET
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
—    Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 —
Oct 18, 2023 04:00 pm ET
Alkermes to Report Third Quarter Financial Results on October 25, 2023
DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023 to discuss the company's third quarter financial results as well as initial clinical data related to ALKS 2680, the company's novel, investigational orexin 2 receptor agonist in development for the treatment of narcolepsy, that will be presented at World Sleep Congress.
Oct 16, 2023 12:30 pm ET
Celebrating Global Diversity Awareness Month at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / October 16, 2023 / Alkermes
Oct 13, 2023 10:45 am ET
Take Time During Mental Health Awareness Week To Review These Resources
NORTHAMPTON, MA / ACCESSWIRE / October 13, 2023 / Mental Health conditions among adults are on the rise across the country, which makes mental health screening more important than ever. Check out this helpful tool from Mental Health America that may help determine if you or a loved one are experiencing symptoms of a mental health condition. https://lnkd.in/g53j4Ut
Oct 11, 2023 12:00 pm ET
Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2023 / Alkermes
Oct 10, 2023 05:00 pm ET
Mural Oncology to Host Investor Webcast on October 17
—  Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET —
Oct 10, 2023 07:00 am ET
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist —
Sep 21, 2023 01:00 pm ET
Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month
NORTHAMPTON, MA / ACCESSWIRE / September 21, 2023 / Alkermes
Sep 19, 2023 11:05 am ET
Alkermes Pathways Research Awards Is Now Accepting Applications!
NORTHAMPTON, MA / ACCESSWIRE / September 19, 2023 / The Alkermes Pathways Research Awards are open for applications! This program is open to all early-career investigators studying bipolar disorder or schizophrenia.
Sep 18, 2023 01:15 pm ET
Alkermes Commemorates World Suicide Prevention Day
NORTHAMPTON, MA / ACCESSWIRE / September 18, 2023 / Alkermes
Sep 11, 2023 07:00 am ET
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy —
Sep 07, 2023 03:15 pm ET
Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program
- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -
Aug 28, 2023 10:35 am ET
Alkermes Honors Women's Equality Day
NORTHAMPTON, MA / ACCESSWIRE / August 28, 2023 / Alkermes
Aug 21, 2023 10:45 am ET
Back to College? Talk to Your Student About Alcohol
NORTHAMPTON, MA / ACCESSWIRE / August 21, 2023 / Alkermes
Jul 26, 2023 07:00 am ET
Alkermes plc Reports Second Quarter 2023 Financial Results
— Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA® Product Royalties —
Jul 24, 2023 01:45 pm ET
Alkermes Awarded 2023 Platinum Bell Seal for Workplace Mental Health
NORTHAMPTON, MA / ACCESSWIRE / July 24, 2023 / Alkermes is honored to be selected for the Bell Seal for Workplace Mental Health at Platinum for the second consecutive year. This award, given annually by Mental Health America recognizes our commitment to fostering a mentally healthy workplace.
Jul 19, 2023 04:00 pm ET
Alkermes to Report Second Quarter Financial Results on July 26, 2023
DUBLIN, July 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to discuss the company's second quarter financial results.
Jul 19, 2023 11:30 am ET
Alkermes Celebrates Pride Month
NORTHAMPTON, MA / ACCESSWIRE / July 19, 2023 / Alkermes
Jul 17, 2023 11:15 am ET
Celebrating 15 Years of Alkermes in Action
NORTHAMPTON, MA / ACCESSWIRE / July 17, 2023 / This year, we're celebrating 15 years of "Alkermes in Action," our employee-led volunteer program that supports local non-profit organizations through hands-on activities. This month, more than 200 Waltham-based employees participated in our Alkermes in Action day of service to support people and organizations in and around Greater Boston.
Jun 28, 2023 07:30 am ET
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
Sarissa Capital Management LP (“Sarissa”) today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
Jun 27, 2023 01:45 pm ET
Tips for Finding LGBTQ+ Competent Mental Health Care
NORTHAMPTON, MA / ACCESSWIRE / June 27, 2023 / Alkermes
Jun 26, 2023 07:37 am ET
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:
Jun 26, 2023 07:00 am ET
Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders
Recommend Shareholders Vote "For" Alkermes' Seven Director Nominees On Company's White Proxy Card
Jun 22, 2023 06:25 am ET
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
Sarissa Capital Management LP (“Sarissa”) today made the following additional statement regarding the recent report on Alkermes plc (NASDAQ: ALKS) issued by independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”):
Jun 21, 2023 02:15 pm ET
DYK: The LGBTQ+ Community Is at Greater Risk for Substance Abuse
NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Alkermes:
Jun 20, 2023 09:33 am ET
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):
Jun 20, 2023 07:00 am ET
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board
Recognizes Alkermes' Value Enhancement Plan, Board Refreshment and Business Momentum
Jun 16, 2023 01:50 pm ET
Juneteenth Reflections From Alkermes' Harold Weekes, Sr. Director, Human Resources
NORTHAMPTON, MA / ACCESSWIRE / June 16, 2023 / Alkermes
Jun 15, 2023 12:15 pm ET
Reflecting on Stigmas Surrounding Men’s Health During Men’s Health Week 2023
NORTHAMPTON, MA / ACCESSWIRE / June 15, 2023 / This Men's Health Week, Alkermes is shining a light on some of the unique health risks that may affect men related to mental health and excessive alcohol consumption.
Jun 15, 2023 07:58 am ET
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:
Jun 14, 2023 02:30 pm ET
Alkermes Participates in ALPFA’s Latina Summit
NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / Alkermes
Jun 13, 2023 07:20 am ET
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
Jun 13, 2023 07:00 am ET
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
Sarissa's Proposed Candidates Would Not Bring New Skills to the Board
Jun 09, 2023 07:00 am ET
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes (NASDAQ: ALKS) accessible at the link below:
Jun 08, 2023 07:00 am ET
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation
Strategic, Operational and Governance Enhancements Have Driven Strong Stock Price Performance and TSR Outperformance in Comparison to Peers
Jun 07, 2023 01:15 pm ET
The Impact of Alkermes Inspiration Grants
NORTHAMPTON, MA / ACCESSWIRE / June 7, 2023 / Alkermes
Jun 06, 2023 06:00 am ET
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
—  Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million —
Jun 05, 2023 07:00 am ET
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
Jun 01, 2023 04:01 pm ET
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
—  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business —
May 31, 2023 04:00 pm ET
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN, May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences.
May 25, 2023 04:15 pm ET
May 16, 2023 07:00 am ET
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences
̶  Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder  ̶
May 09, 2023 07:00 am ET
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
–  Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented –
May 08, 2023 04:41 pm ET
Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process
DUBLIN, May 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available on the Investor Relations section of the company's website at www.alkermes.com.
May 08, 2023 12:35 pm ET
Alkermes Named Among Top 100 Companies Leading in Wellbeing by Ibec
NORTHAMPTON, MA / ACCESSWIRE / May 8, 2023 / Alkermes
May 04, 2023 10:30 am ET
Alkermes Athlone Shortlisted for Gradirleand’s 17th Annual Graduate Recruitment Awards
NORTHAMPTON, MA / ACCESSWIRE / May 4, 2023 / Alkermes' Athlone site was recently shortlisted for gradireland's 17th annual Graduate Recruitment Awards! This award recognizes outstanding graduate intake programs across Ireland.
May 02, 2023 01:30 pm ET
Alkermes Athlone Receives Award at Ireland’s 2023 Health & Safety Excellence Awards
NORTHAMPTON, MA / ACCESSWIRE / May 2, 2023 / Alkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland's 2023 Health & Safety Excellence Awards. This recognition is a testament to our employees' focus on building a culture of safety and risk management in Athlone. Learn more about this honor: https://lnkd.in/eHzGMjC
May 01, 2023 01:30 pm ET
Alkermes Inspiration Grants Now Open for Applications
NORTHAMPTON, MA / ACCESSWIRE / May 1, 2023 / The 2023 Alkermes Inspiration Grants® program is now open for applications! These grants are designed to support programs or organizations for people affected by serious mental illness, addiction and cancer. Apply here: https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2023
Apr 26, 2023 01:15 pm ET
Clinical Trials Integral to Providing More Treatment Options for Platinum-Resistant Ovarian Cancer (PROC)
NORTHAMPTON, MA / ACCESSWIRE / April 26, 2023 / Patients diagnosed with platinum-resistant Ovarian Cancer (PROC) often face poor prognosis due to the limited treatment options. Watch this video to learn more about PROC and why clinical trials are critical for researching potential options.
Apr 26, 2023 07:00 am ET
Alkermes plc Reports First Quarter 2023 Financial Results
—  First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio —
Apr 25, 2023 07:00 am ET
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
DUBLIN, April 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
Apr 24, 2023 11:45 am ET
Alkermes' Katie Joyce To Speak at Women in Bio 2023
NORTHAMPTON, MA / ACCESSWIRE / April 24, 2023 / Last week, Katie Joyce, VP of Corporate Affairs, participated in a panel discussion at this year's Women in Bio (WIB) Management Track event featuring women leaders in life science. This year's event gave attendees the opportunity to connect with industry leaders and hear from a panel of executive women leaders discussing their career paths and individual experiences. To learn more about Women In Bio, visit their website: https://lnkd.in/ePbUHdj
Apr 21, 2023 10:55 am ET
Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program To Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer
DUBLIN / ACCESSWIRE / April 21, 2023 / Alkermes plc (Nasdaq:ALKS) recently announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.
Apr 20, 2023 02:00 pm ET
Alcohol Use Disorder Doesn’t Discriminate
NORTHAMPTON, MA / ACCESSWIRE / April 20, 2023 / Alkermes
Apr 19, 2023 04:00 pm ET
Alkermes to Report First Quarter Financial Results on April 26, 2023
DUBLIN, April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 26, 2023 to discuss the company's first quarter financial results.
Apr 18, 2023 07:00 am ET
Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business
DUBLIN, April 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the separation in the second half of 2023.
Apr 12, 2023 03:30 pm ET
Alkermes Recommits to Equality on Equal Pay Day 2023
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Alkermes (NASDAQ:ALKS)
Mar 23, 2023 11:00 am ET
Alkermes Named to Ragan Communications and PR Daily’s Top Places To Work 2023
NORTHAMPTON, MA / ACCESSWIRE / March 23, 2023 / Alkermes was recently named to Ragan Communications and PR Daily' list of Top Places to Work for 2023! If you are interested in joining Team Alkermes, check out our careers page: https://bit.ly/3J6TBA0
Mar 23, 2023 07:00 am ET
Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness
DUBLIN, March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry. ENLIGHTEN-Early evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness. To qualify for participation as "early in illness", patients had to have less than 24 weeks
Mar 15, 2023 04:00 pm ET
Alkermes to Participate in the Stifel 2023 CNS Days
DUBLIN, March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET (2:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Feb 16, 2023 06:00 am ET
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
—  Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 —
Feb 09, 2023 03:00 pm ET
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023
DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 16, 2023 to discuss the company's fourth quarter and year-end 2022 financial results. Management will also discuss financial expectations for 2023 and provide an update on the company.
Jan 17, 2023 06:00 am ET
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK —  
Dec 28, 2022 03:00 pm ET
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
DUBLIN, Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 11, 2023 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 30, 2022 03:00 pm ET
Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference
DUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may  be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 22, 2022 03:00 pm ET
Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference
DUBLIN, Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET (7:40 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 09, 2022 01:30 pm ET
The Alkermes Team Is Motivated by Personal Experience With Serious Mental Illness, Addiction and Cancer
NORTHAMPTON, MA / ACCESSWIRE / November 9, 2022 / Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success. We strive to support our employees' well-being in a transparent, diverse, inclusive and collaborative culture and provide employees with training, support and resources to help them to succeed professionally while appropriately balancing their professional and personal lives. Beyond our employee initiatives, we are
Nov 08, 2022 03:00 pm ET
Alkermes to Participate in the Stifel Healthcare Conference
DUBLIN, Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 07, 2022 01:35 pm ET
Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants(R) Program
DUBLIN, IRELAND / ACCESSWIRE / November 7, 2022 / - Alkermes plc (Nasdaq:ALKS) announced the 2022 recipients of the Alkermes Inspiration Grants® program. Grants were awarded to nine nonprofit organizations working to address the needs of people living with alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and cancer. The selected programs also have a focus on addressing unmet needs in historically under-resourced or underrepresented communities with longstanding and widespread health disparities.
Nov 03, 2022 11:55 am ET
Alkermes Celebrates Hispanic Americans Who Are Trailblazers in the Mental Health Field
NORTHAMPTON, MA / ACCESSWIRE / November 3, 2022 / This Hispanic Heritage Month, we celebrated the contributions of Hispanic Americans to the field of mental health. Learn about a few trailblazers above.
Nov 02, 2022 07:02 am ET
Alkermes plc Reports Third Quarter 2022 Financial Results
—  Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio —
Nov 02, 2022 07:00 am ET
Alkermes plc Announces Intent to Separate Oncology Business
— Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business —
Nov 01, 2022 10:50 am ET
A Message on Corporate Responsibility From Richard F. Pops, Alkermes CEO
The importance of corporate responsibility comes more sharply into focus with each passing year. The challenges we face as a global community are significant and growing as we grapple with the realities and impacts of systemic racism, political conflict, climate change and the lingering effects of a global pandemic.
Oct 28, 2022 11:00 am ET
Alkermes Named Awardee of NEEBC's Best Practices Award 2021
NORTHAMPTON, MA / ACCESSWIRE / October 28, 2022 / We are honored to be recognized as an awardee of New England Employee Benefits Council (NEEBC)'s Best Practices Award for 2022! This award recognizes our competitive benefits offerings and demonstrates our continued commitment to making Alkermes a great place to work. Learn more: https://bit.ly/3r9UXQv
Oct 27, 2022 07:00 am ET
Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program
– 6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer –
Oct 26, 2022 04:01 pm ET
Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022
DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Wednesday, Nov. 2, 2022 to discuss the company's third quarter financial results. Management will also provide an update on the company.
Sep 28, 2022 07:00 am ET
Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program
-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project --
Sep 20, 2022 07:00 am ET
Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress
̶  Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference  ̶
Jul 27, 2022 07:00 am ET
Alkermes plc Reports Second Quarter 2022 Financial Results
—    Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales —
Jul 20, 2022 04:00 pm ET
Alkermes to Report Second Quarter Financial Results on July 27, 2022
DUBLIN, July 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022 to discuss the company's second quarter financial results. Management will also provide an update on the company.
Jul 06, 2022 07:04 am ET
Sarissa Capital Comments on Alkermes Annual Meeting
Sarissa Capital Management LP (“Sarissa”) today made the following statement on Alkermes PLC (NASDAQ: ALKS) regarding how it intends to vote at the upcoming Alkermes annual meeting and the reasons therefor:
Jun 08, 2022 04:00 pm ET
Alkermes to Participate in the Goldman Sachs Healthcare Conference
DUBLIN, June 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT (5:40 p.m. ET/10:40 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Jun 01, 2022 04:00 pm ET
Alkermes to Participate in the Jefferies Healthcare Conference
DUBLIN, June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Jun 01, 2022 07:00 am ET
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types –
May 27, 2022 09:43 am ET
Sarissa Condemns Poor Corporate Governance at Alkermes
Sarissa Capital Management LP (“Sarissa”) today made the following statement regarding Alkermes plc (NASDAQ: ALKS):
May 26, 2022 05:36 pm ET
May 09, 2022 07:00 am ET
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation –
May 02, 2022 07:00 am ET
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
̶   Clinical, Epidemiology and Health Economics and Outcomes Research to Advance Understanding of Treatment Patterns and Patient Experiences   ̶
Apr 27, 2022 07:00 am ET
Alkermes plc Reports First Quarter 2022 Financial Results
—  First Quarter Revenues of $278.5 Million Reflect Strong Performance of LYBALVI®, ARISTADA® and VIVITROL® —
Apr 20, 2022 04:00 pm ET
Alkermes to Report First Quarter Financial Results on April 27, 2022
DUBLIN, April 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 27, 2022 to discuss the company's first quarter financial results. Management will also provide an update on the company.
Apr 19, 2022 07:30 am ET
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
DUBLIN, April 19, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson. Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal® Technology, which enabled a number of successful products, such as INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® and CABENUVA®. Janssen partially terminated the agreements in the United States ef
Apr 07, 2022 07:00 am ET
Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society
– Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness –
Mar 22, 2022 04:00 pm ET
Alkermes to Participate in the Stifel 2022 CNS Days
DUBLIN, March 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022 CNS Days on Tuesday, March 29, 2022 at 8:30 a.m. ET (1:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Mar 01, 2022 06:00 am ET
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022. New data in patients with platinum-resistant ovarian cancer from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of intravenously administered (IV) nemvaleukin as a monotherapy and in combination with pembrolizu
Feb 17, 2022 06:00 am ET
Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium
DUBLIN, Feb. 17, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place Feb. 17-19, 2022.
Feb 16, 2022 06:00 am ET
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022
DUBLIN, Feb. 16, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for 2022.
Feb 08, 2022 06:00 am ET
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness
DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI® (olanzapine and samidorphan) compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness. The study met its pre-specified primary endpoint, as patients treated with LYBALVI experienced statistically significantly less weight gain than patients treated with olanzapine at Week 1
Feb 02, 2022 03:00 pm ET
Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022
DUBLIN, Feb. 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 16, 2022 to discuss the company's fourth quarter and year-end 2021 financial results. Management will also discuss financial expectations for 2022 and provide an update on the company.
Jan 18, 2022 06:00 am ET
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pemb
Jan 06, 2022 06:00 am ET
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
DUBLIN, Jan. 6, 2022 /PRNewswire/ -- Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. This research was conducted in support of Alkermes' commitment to understanding the unique needs of people living with BD-I and supporting increased disease awareness and education. 
Jan 05, 2022 03:00 pm ET
Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 12, 2022 at 11:15 a.m. EST (4:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 24, 2021 03:00 pm ET
Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference
DUBLIN, Nov. 24, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thursday, Dec. 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 19, 2021 06:00 am ET
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
DUBLIN, Nov. 19, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social justice initiatives and has been widely recognized for his work promoting diversity and excellence in science and addressing health disparities. He currently ser
Nov 11, 2021 06:00 am ET
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
DUBLIN, Nov. 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor element-1 silencing transcription factor) HDAC (histone deacetylase) inhibitor candidate for the treatment of neurodegenerative and neurological disorders. ALKS 1140 is designed to increase functional synaptic connections and synaptic integrity in the brain.
Nov 09, 2021 03:00 pm ET
Alkermes to Take Part in the Stifel Virtual Healthcare Conference
DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on Tuesday, Nov. 16, 2021 at 9:20 a.m. ET (2:20 p.m. GMT). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 08, 2021 03:05 pm ET
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology. The terminations impact know-how royalties related to sales of long-acting paliperidone products, such as INVEGA SUSTENNA® and INVEGA TRINZA®, and other products in the United States. Pursuant
Nov 03, 2021 07:00 am ET
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021. The poster will include data from the ION-01 study, a phase 2 trial evaluating intravenous nemvaleukin in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma that had previously progressed on a
Oct 29, 2021 07:00 am ET
Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences
DUBLIN, Oct. 29, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall. The meetings include:
Oct 27, 2021 07:00 am ET
Alkermes plc Reports Third Quarter 2021 Financial Results
DUBLIN, Oct. 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2021.
Oct 26, 2021 07:00 am ET
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin alfa (nemvaleukin), in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is a novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. As previously announced, ARTISTRY-7 is being conduct
Oct 25, 2021 07:00 am ET
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, in combination with pembrolizumab, an anti-PD-1 antibody, for the treatment of platinum-resistant ovarian cancer. The FDA previously granted Fast Track designation and Orphan Drug designation to nemvaleukin for the treatment of mucosal melanoma.
Oct 20, 2021 04:00 pm ET
Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021
DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 27, 2021 to discuss the company's third quarter 2021 financial results. Management will also provide an update on the company.
Oct 18, 2021 07:00 am ET
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
DUBLIN, Oct. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U.S.) for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.
Sep 22, 2021 04:00 pm ET
Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 29, 2021 at 8:40 a.m. ET (1:40 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Sep 22, 2021 07:00 am ET
New Survey Provides Insights Into Drinking Behaviors During the Pandemic
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), found that 17% of respondents aged 21 and over reported drinking patterns that met the survey criteria for "heavy drinking"*. Of those surveyed whose responses met the criteria for heavy drinking, only 13% reported that they were undergoing treatment for their drinking at the time of the survey. The survey results also suggest that family and friends can play an important role in motivating people with h
Sep 13, 2021 07:01 am ET
Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021. The presentations will include a trial-in-progress poster for ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin monotherapy in patients with melanoma who have been previously treated with
Sep 09, 2021 07:00 am ET
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program
DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Sept. 13, 2021. This competitive grant program is designed to support the next generation of researchers working on the front lines to advance understanding and awareness of disease states in the field of neuroscience. In its fourth year, the program will offer grants to early-career investigators who have demonstrated a commitment to helping people living with schizophrenia, bipolar disorder, alcohol use diso
Sep 02, 2021 04:00 pm ET
Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference
DUBLIN, Sept. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, Sept. 9, 2021 at 8:50 a.m. ET (1:50 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Aug 02, 2021 07:00 am ET
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Aug. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal melanoma. Earlier this year, the FDA also granted orphan drug designation to nemvaleukin for the treatment of mucosal melanoma. The company recently initiated enrollment in ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemval
Jul 28, 2021 07:00 am ET
Alkermes plc Reports Second Quarter 2021 Financial Results
DUBLIN, July 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021.
Jul 23, 2021 07:00 am ET
Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program
DUBLIN, July 23, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or cancer, including programs serving historically under-resourced or underrepresented communities, including Black, Indigenous and people of color (BIPOC), LGBTQ+ individuals, veterans, women and people impacted by the U.S. criminal justice system.
Jul 21, 2021 04:00 pm ET
Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021
DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 28, 2021 to discuss the company's second quarter 2021 financial results. Management will also provide an update on the company.
Jun 30, 2021 07:00 am ET
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence
DUBLIN, June 30, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans with alcohol dependence at the 2021 Research Society on Alcoholism (RSA) Scientific Meeting/International Society for Biomedical Research on Alcoholism (ISBRA) Conference, which took place virtually June 19-23, 2021.
Jun 22, 2021 07:00 am ET
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcohol dependence and encourage people who are rethinking their relationship with alcohol to reach out to their healthcare provider. The My Relationship with Alcohol website aims to help decrease the stigma surrounding alcohol dependence by providing disease state edu
Feb 18, 2021 03:00 pm ET
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 24, 2021 at 9:20 a.m. ET (2:20 p.m. GMT). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Feb 11, 2021 06:00 am ET
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
DUBLIN, Feb. 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2020 and provided financial expectations for 2021.
Feb 04, 2021 03:00 pm ET
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company's fourth quarter and year-end 2020 financial results. Management will also discuss financial expectations for 2021 and provide an update on the company.
Jan 14, 2021 06:00 am ET
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension (XR-NTX) administered once every three weeks plus oral extended-release bupropion administered daily as a combination treatment for adults with moderate or severe methamphetamine use disorder (MUD) were published today by Dr. Madhukar H. Trivedi et al. in the New England Journal of Medicine (NEJM).1 This is the second published study evaluating this combination regimen for the treatment of MUD.2 
Jan 06, 2021 03:00 pm ET
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 13, 2021 at 10:00 a.m. EST (3:00 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Jan 06, 2021 06:00 am ET
Alkermes Announces Updates to Executive Leadership Team
DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS), a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology, today announced a series of changes to its executive leadership team. Blair C. Jackson has been appointed chief operating officer (COO) and Iain M. Brown will assume the role of chief financial officer (CFO), replacing James M. Frates. Mr. Frates will leave the company following a 20-year career at Alkermes to pursue another opportunity.  
Dec 29, 2020 08:38 am ET
Thinking about buying stock in Immersion Corp, IRIDEX Corp, One Stop Systems, Phio Pharmaceuticals, or Alkermes?
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMR, IRIX, OSS, PHIO, and ALKS.
Dec 29, 2020 06:00 am ET
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Application (NDA) resubmission for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with bipolar I disorder, and has assigned the application a new Prescription Drug User Fee Act (PDUFA) target action date of June 1, 2021.
Dec 10, 2020 06:00 am ET
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance and enhance shareholder value, as the company continues to advance its mission of developing new medicines designed to have a real-world impact in the treatment of serious mental illness, addiction and cancer. The Plan includes a commitment to multi-year profitability targets, a review and optimization of the company's cost structure, potential monetization of non-core assets, and continued governance
Nov 17, 2020 06:00 am ET
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with bipolar I disorder. Following a remote review of manufacturing records, FDA stated that resolution of certain conditions related to the tablet coating process at the company's Wilmington, OH facility is required before ALKS 3831 may be approved. The CRL did not identify or
Nov 09, 2020 07:01 am ET
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
DUBLIN, Nov. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from the ARTISTRY clinical development program for ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, being held virtually Nov. 11-14, 2020. The company will present preliminary safety, tolerability and pharmacokinetic/pharmacodynamic data from the dose-escalation stage of ARTISTRY-2, the ongoing phase 1/2 study evaluating ALKS 4230 administered subcutaneously
Oct 29, 2020 10:24 am ET
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulties impacting the conference call provider.  The company now plans to host the conference call and webcast presentation at 10:30 a.m. ET (2:30 p.m. GMT) on Thursday, Oct. 29, 2020.
Oct 29, 2020 07:00 am ET
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year 2020.
Oct 22, 2020 04:00 pm ET
Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss the company's third quarter 2020 financial results. Management will also provide an update on the company.
Jul 29, 2020 07:00 am ET
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
DUBLIN, July 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2020 and provided updated financial expectations for full-year 2020. The company had previously withdrawn its 2020 financial expectations due to uncertainties regarding the impact of the COVID-19 pandemic on its business.
Jul 22, 2020 04:00 pm ET
Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results
DUBLIN, July 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 29, 2020 to discuss the company's second quarter 2020 financial results. Management will also provide an update on the company.
Jun 29, 2020 07:00 am ET
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
DUBLIN, June 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1, 2020. This competitive grant program is designed to support the next generation of researchers working on the front lines to advance understanding and awareness of disease states in the field of neuroscience. In its third year, the program will offer grants to early-career investigators who have demonstrated their commitment to helping people living with substance use disorders (SUDs), schizophrenia, a
Jun 24, 2020 07:00 am ET
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
DUBLIN, June 24, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonprofit organizations in their work to rapidly address pandemic-related needs for people living with addiction, serious mental illness, or cancer. More than 350 applications were submitted in May 2020 for this highly competitive program.
Jun 22, 2020 09:01 am ET
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, with lucitanib, Clovis' investigational angiogenesis inhibitor. The data will be presented during a poster session at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place June 22-24, 2020.
Jun 04, 2020 04:00 pm ET
Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
DUBLIN, June 4, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 at 9:40 a.m. ET (2:40 p.m. BST). The webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
May 27, 2020 07:00 am ET
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
DUBLIN, May 27, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new research from its schizophrenia portfolio at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting, taking place virtually May 29-30, 2020.
May 20, 2020 07:00 am ET
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
DUBLIN, May 20, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that data from its phase 3b ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study were published in the Journal of Clinical Psychiatry. ALPINE was a six-month study evaluating the efficacy and safety of the ARISTADA INITIO® (aripiprazole lauroxil) one-day initiation regimen, consisting of ARISTADA INITIO and one single dose of 30 mg of oral aripiprazole, together with the ARISTADA® (aripiprazole lauroxil) two-month dose in patients experiencing an acute exacerbation of schizop
May 14, 2020 07:00 am ET
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
DUBLIN, May 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the Schizophrenia International Research Society (SIRS).
May 11, 2020 07:00 am ET
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
DUBLIN, May 11, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the expansion of several programs and services in support of patient access to its proprietary medicines during the COVID-19 crisis. During this unprecedented and rapidly evolving situation, the company remains focused on helping to assure that patients have uninterrupted access to ARISTADA® (aripiprazole lauroxil), an injectable atypical antipsychotic for the treatment of schizophrenia in adults, and VIVITROL® (naltrexone for extended-release injectable suspension), indicated for the treatment of alcohol depend
May 06, 2020 04:00 pm ET
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
DUBLIN, May 6, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 2020 Bank of America Securities Virtual Health Care Conference on Wednesday, May 13, 2020 at 9:40 a.m. ET (2:40 p.m. BST). The webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
May 04, 2020 07:00 am ET
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
DUBLIN, May 4, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company is now accepting applications for its newly-established COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program. The company has redeployed 2020 funding for the Alkermes Inspiration Grants program to provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to urgently address COVID-19-related needs for people living with addiction, serious mental illness or cancer. The application period is now open and will run th
Apr 29, 2020 07:00 am ET
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
DUBLIN, April 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2020, and provided commentary related to the impact of the COVID-19 pandemic on the business.
Apr 22, 2020 04:00 pm ET
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
DUBLIN, April 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial results. Management will also provide an update on the company.
Apr 22, 2020 07:00 am ET
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
DUBLIN, April 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its investigational, immunotherapy candidate, ALKS 4230, in the Journal for ImmunoTherapy of Cancer (JITC). ALKS 4230, a novel cytokine, is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the interleukin-2 (IL-2)-induced activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex.
Nov 12, 2019 03:01 pm ET
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov. 19, 2019 at 1:15 p.m. ET (6:15 p.m. GMT) from New York. In addition, Alkermes' corporate presentation will be webcast live at the Jefferies London Healthcare Conference on Thursday, Nov. 21, 2019 at 4:00 p.m. GMT (11:00 a.m. ET) from London, U.K.  These presentations may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Nov 12, 2019 06:00 am ET
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis, and Alkermes' transfer to Biogen Inc. (Nasdaq: BIIB) of the New Drug Application and other regulatory documentation related to VUMERITY.
Nov 08, 2019 06:00 am ET
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
DUBLIN, Nov. 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting in National Harbor, MD. ALKS 4230 is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the IL-2-induced activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The company presented preliminary clinical data from
Nov 04, 2019 06:00 am ET
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from its ARTISTRY clinical development program related to ALKS 4230, an investigational engineered fusion protein designed to selectively expand cancer-fighting immune cells, at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting being held Nov. 6-10, 2019 in National Harbor, MD. The company will present preliminary clinical data from the ARTISTRY-1 phase 1/2 study investigating ALKS 4230 as monotherapy and in combination with pembrolizumab in adults with advanced s
Oct 30, 2019 07:30 am ET
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of...
Oct 30, 2019 07:30 am ET
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive, worldwide license to commercialize VUMERITY and intends to make it available in the United States in the near fu
Oct 23, 2019 07:00 am ET
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2019 and the implementation of a restructuring plan following a review of the company's operations, cost structure and growth opportunities.
Oct 21, 2019 07:00 am ET
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
DUBLIN, Oct. 21, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230, Alkermes' immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex.
Oct 16, 2019 04:01 pm ET
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
DUBLIN, Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, October 23, 2019, to discuss the company's third quarter 2019 financial results. Management will also provide an update on the company.
Oct 07, 2019 07:00 am ET
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the  presentation of new health economics and outcomes research at the 32nd Annual Psych Congress (Psych Congress), which took place Oct. 3-6, 2019 in San Diego. This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious mental illness.
Sep 26, 2019 04:01 pm ET
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at 7:45 a.m. ET (12:45 p.m. BST) from New York. The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Sep 13, 2019 07:00 am ET
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today.
Jul 30, 2019 07:30 am ET
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.